Steve CohenSell
EBS · Transaction Dec 11, 2024 · Filed Jan 10, 2025 · $1,001 to $15,000
NEW YORK STOCK EXCHANGE, INC. · EBS
+0.00% · +$0.0000 · Vol Not reported
Pre-market · updated 04:58:29 ET
Emergent BioSolutions Inc
Biotechnology
$4.84
Veridion Score
BETAMEDIUM CONF · 5/6 factorsFri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET · EBS
MethodologyEBS
Emergent BioSolutions Inc
Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
65/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is EBS moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Emergent BioSolutions Inc
PHARMACEUTICAL PREPARATIONSListed since
2006
Employees
900
Country
US
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$4.84
Last session
Day high
$4.84
Last session
Day low
$4.84
Last session
Previous close
$4.84
52W high
$13.90
-65.18% from high
52W low
$4.84
0% of range
Market cap
$248.2M
P/E
4.75×
EPS
$-2.7300
Beta
1.11
Shares out
51.3M
Avg volume
909.4K
VWAP
$4.84
Last session
Price history computed in-house
1W
-34.68%
1M
-39.88%
3M
-43.06%
1Y
-43.52%
YTD
-60.84%
SMA 50 $7.86 · below
SMA 200 $9.54 · below
52W position 0%
EBS overview
Related filings and maps
Public disclosures
Congress activity in EBS
Official filing ↗
Josh GottheimerSell
EBS Common Stock · Transaction Nov 5, 2021 · Filed Dec 13, 2021 · Amount pending receipt enrichment
EBS Common Stock · Transaction Oct 18, 2021 · Filed Nov 15, 2021 · Amount pending receipt enrichment
Josh GottheimerSell
EBS Common Stock · Transaction Sep 15, 2021 · Filed Oct 13, 2021 · Amount pending receipt enrichment
Josh GottheimerSell
EBS Common Stock · Transaction Feb 23, 2021 · Filed Mar 10, 2021 · Amount pending receipt enrichment
Federal contracts
EBS contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for EBS in this window.
Lobbying spend
EBS lobbying filings, year to date.
Registered lobbying filings matched to Emergent BioSolutions Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for EBS in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for EBS.
Options
Sovereign unlock shows live options positioning for EBS.